Infliximab Limits Injury in Myocardial Infarction

J Am Heart Assoc. 2024 May 7;13(9):e032172. doi: 10.1161/JAHA.123.032172. Epub 2024 May 3.

Abstract

Background: The purpose of this study was to investigate a therapeutic approach targeting the inflammatory response and consequent remodeling from ischemic myocardial injury.

Methods and results: Coronary thrombus aspirates were collected from patients at the time of ST-segment-elevation myocardial infarction and subjected to array-based proteome analysis. Clinically indistinguishable at myocardial infarction (MI), patients were stratified into vulnerable and resilient on the basis of 1-year left ventricular ejection fraction and death. Network analysis from coronary aspirates revealed prioritization of tumor necrosis factor-α signaling in patients with worse clinical outcomes. Infliximab, a tumor necrosis factor-α inhibitor, was infused intravenously at reperfusion in a porcine MI model to assess whether infliximab-mediated immune modulation impacts post-MI injury. At 3 days after MI (n=7), infliximab infusion increased proregenerative M2 macrophages in the myocardial border zone as quantified by immunofluorescence (24.1%±23.3% in infliximab versus 9.29%±8.7% in sham; P<0.01). Concomitantly, immunoassays of coronary sinus samples quantified lower troponin I levels (41.72±7.34 pg/mL versus 58.11±10.75 pg/mL; P<0.05) and secreted protein analysis revealed upregulation of injury-modifying interleukin-2, -4, -10, -12, and -18 cytokines in the infliximab-treated cohort. At 4 weeks (n=12), infliximab treatment resulted in significant protective influence, improving left ventricular ejection fraction (53.9%±5.4% versus 36.2%±5.3%; P<0.001) and reducing scar size (8.31%±10.9% versus 17.41%±12.5%; P<0.05).

Conclusions: Profiling of coronary thrombus aspirates in patients with ST-segment-elevation MI revealed highest association for tumor necrosis factor-α in injury risk. Infliximab-mediated immune modulation offers an actionable pathway to alter MI-induced inflammatory response, preserving contractility and limiting adverse structural remodeling.

Keywords: TNFα inhibition; immune modulation; infliximab; myocardial infarction; porcine model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Animals
  • Coronary Thrombosis / drug therapy
  • Coronary Thrombosis / prevention & control
  • Disease Models, Animal*
  • Female
  • Humans
  • Infliximab* / pharmacology
  • Infliximab* / therapeutic use
  • Macrophages / drug effects
  • Macrophages / immunology
  • Macrophages / metabolism
  • Male
  • Middle Aged
  • Myocardium / immunology
  • Myocardium / metabolism
  • Myocardium / pathology
  • ST Elevation Myocardial Infarction / drug therapy
  • ST Elevation Myocardial Infarction / immunology
  • Stroke Volume / drug effects
  • Swine
  • Troponin I / blood
  • Troponin I / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • Ventricular Function, Left / drug effects
  • Ventricular Remodeling* / drug effects

Substances

  • Infliximab
  • Tumor Necrosis Factor-alpha
  • Troponin I